查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553664

運動醫學血液生物標記市場規模、佔有率、趨勢分析報告：按類型、地區、細分市場預測，2024-2030 年

Blood-based Biomarker For Sports Medicine Market Size, Share & Trends Analysis Report By Type (CK, Myoglobin, Lactate, WBC, Urea, CRP), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

運動醫學市場成長和趨勢的血液生物標記：

Grand View Research, Inc.的最新報告顯示，到2030年，運動醫學用血液生物標記的全球市場規模預計將達到11.6億美元，2024年至2030年的複合年成長率為6.7%，預計將擴大。

推動該市場的關鍵因素是對個人化健康的日益關注、生物標記技術的進步以及對準確表現和恢復評估的需求不斷增加。此外，人們對運動相關傷害的認知不斷提高以及對精確診斷的需求也有助於市場的成長和創新。

日益關注研發和增加對運動醫學的投資是市場擴張的主要動力。隨著運動醫學領域的發展，人們越來越關注透過先進的生物標記來了解運動員複雜的生理反應。對運動醫學研究的投資正在推動以血液為基礎的生物標記技術的重大進步。公司和研究機構正在大力投資開發高通量篩檢方法和先進的資料分析，以改善生物標記的檢測和解釋。公共和私人組織不斷增加的投資進一步推動了運動醫學領域對先進生物標記的需求。

此外，還研究了生物標記的可預測性，以主動預測受傷風險。根據發表在《生理學前沿》上的一項研究，高級研究重點關注氧化壓力和發炎的生物標記，以預測損傷易感性。這種預測能力對於預防策略很有價值，可以幫助運動員採取主動措施避免受傷。因此，運動醫學中基於血液的生物標記市場正在經歷顯著成長。

運動醫學市場血液生物標記報告亮點

  • 肌酸激酶 (CK) 細分市場在 2023 年佔據最大收益佔有率，達到 18.0%。人們對傷害預防和管理的日益關注，以及運動員和運動團隊對防止過度訓練和最佳化恢復的重要性的認知不斷提高，推動了對 CK 測試的需求。
  • 從事運動醫學血液生物標記市場的主要企業包括 Abbott、BIOMERIEUX、F. Hoffmann-La Roche Ltd.、ARUP Laboratories、Siemens Healthineers AG 和 RayBiotech, Inc.。此外，新興市場正在見證新參與企業推出創新新產品，以及主要市場參與企業之間建立策略聯盟來開發新產品。
  • 2023 年 3 月，雅培獲得美國FDA 批准首個商業化 TBI 血液檢測，使其在美國醫院廣泛使用。此測試可檢測血液中的兩種生物標記物，當它們含量較高時，與腦損傷密切相關。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章運動醫學市場變數、趨勢和範圍的血液生物標記

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 運動醫學基於血液的生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章運動醫學血液生物標記市場：按類型估計和趨勢分析

  • 全球運動醫學血液生物標記市場：按類型分類的儀表板
  • 全球運動醫學血液生物標記市場：按類型的變異分析
  • 全球運動醫學血液生物標記市場：按類型分類的收益
  • CK
  • 肌紅蛋白
  • 乳酸
  • 白血球計數
  • 尿素
  • ＣＲＰ
  • 脂質和蛋白質氫過氧化物
  • IL-6
  • 其他

第5章運動醫學血液生物標記市場：按類型和地區分類的估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第6章 競爭狀況

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Abbott
    • BIOMERIEUX
    • F. Hoffmann-La Roche Ltd.
    • ARUP Laboratories
    • Siemens Healthineers AG
    • RayBiotech, Inc.
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc.
    • Beckman Coulter, Inc.
    • Randox Laboratories Ltd.
Product Code: GVR-4-68040-436-1

Blood-Based Biomarker For Sports Medicine Market Growth & Trends:

The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.

The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.

Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.

Blood-Based Biomarker For Sports Medicine Market Report Highlights:

  • The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery
  • Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMERIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings
  • In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Sports Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing Demand for Personalized Medicine
      • 3.2.1.2. Increased Focus on Injury Prevention and Recovery
      • 3.2.1.3. Growing R&D and Rising Investments in Sports Medicine s
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory Challenges and Lack of Awareness & Standardization
  • 3.3. Blood-based Biomarker for Sports Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Sports Medicine Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood-based Biomarker for Sports Medicine Market: Type Dashboard
  • 4.2. Global Blood-based Biomarker for Sports Medicine Market: Type Movement Analysis
  • 4.3. Global Blood-based Biomarker for Sports Medicine Market by Type, Revenue
  • 4.4. CK
    • 4.4.1. CK market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Myoglobin
    • 4.5.1. Myoglobin market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Lactate
    • 4.6.1. Lactate market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. WBC
    • 4.7.1. WBC market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Urea
    • 4.8.1. Urea market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.9. CRP
    • 4.9.1. CRP market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.10. Lipid and Protein Hydroperoxides
    • 4.10.1. Lipid and protein hydroperoxides market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.11. IL-6
    • 4.11.1. IL-6 market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.12. Others
    • 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Blood-based Biomarker for Sports Medicine Market: Regional Estimates & Trend Analysis by Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.6. Norway
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.5. New Zealand
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. New Zealand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.6. Taiwan
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Taiwan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.7. Hong Kong
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. Hong Kong market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.8. Singapore
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework/ reimbursement structure
      • 5.5.8.3. Competitive scenario
      • 5.5.8.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.9. Thailand
      • 5.5.9.1. Key country dynamics
      • 5.5.9.2. Regulatory framework/ reimbursement structure
      • 5.5.9.3. Competitive scenario
      • 5.5.9.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.10. Vietnam
      • 5.5.10.1. Key country dynamics
      • 5.5.10.2. Regulatory framework/ reimbursement structure
      • 5.5.10.3. Competitive scenario
      • 5.5.10.4. Vietnam market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.3. Chile
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Chile market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.4. Egypt
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Egypt market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.5. Qatar
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Qatar market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Vendor Landscape
    • 6.2.1. List of key distributors and channel partners
    • 6.2.2. Key customers
    • 6.2.3. Key company market share analysis, 2023
    • 6.2.4. Abbott
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. BIOMERIEUX
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd.
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. ARUP Laboratories
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. Siemens Healthineers AG
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. RayBiotech, Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Thermo Fisher Scientific, Inc.
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Bio-Rad Laboratories, Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives
    • 6.2.12. Beckman Coulter, Inc.
      • 6.2.12.1. Company overview
      • 6.2.12.2. Financial performance
      • 6.2.12.3. Product benchmarking
      • 6.2.12.4. Strategic initiatives
    • 6.2.13. Randox Laboratories Ltd.
      • 6.2.13.1. Company overview
      • 6.2.13.2. Financial performance
      • 6.2.13.3. Product benchmarking
      • 6.2.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 5 Canada blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 6 Mexico blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 7 Europe blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 9 Germany blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 10 UK blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 11 France blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 12 Italy blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 13 Spain blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 14 Denmark blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 15 Sweden blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 16 Norway blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 19 China blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 20 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 21 Taiwan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 22 Hong Kong blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 23 Singapore blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 24 Thailand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 25 Vietnam blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 26 Japan blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 27 India blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 28 South Korea blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 29 Australia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 30 New Zealand blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 31 Latin America blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 32 Latin America blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 33 Brazil blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 34 Argentina blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 35 Chile blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 36 MEA blood-based biomarker for sports medicine market, by region, 2018 - 2030 (USD Million)
  • Table 37 MEA blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 38 South Africa blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 39 Saudi Arabia blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 40 UAE blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 41 Egypt blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)
  • Table 42 Qatar blood-based biomarker for sports medicine market, by type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Blood-based biomarker for sports medicine market: market outlook
  • Fig. 14 Blood-based biomarker for sports medicine competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Blood-based biomarker for sports medicine market driver impact
  • Fig. 18 Blood-based biomarker for sports medicine market restraint impact
  • Fig. 19 Blood-based biomarker for sports medicine market: Type movement analysis
  • Fig. 20 Blood-based Biomarker for Sports Medicine market: Type outlook and key takeaways
  • Fig. 21 CK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Myoglobin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lactate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 WBC market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Urea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CRP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Lipid and protein hydroperoxides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 IL-6 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Global blood-based biomarker for sports medicine market: Regional movement analysis
  • Fig. 31 Global blood-based biomarker for sports medicine market: Regional outlook and key takeaways
  • Fig. 32 Global blood-based biomarker for sports medicine market share and leading players
  • Fig. 33 North America, by country
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. key country dynamics
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada key country dynamics
  • Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico key country dynamics
  • Fig. 40 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK key country dynamics
  • Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany key country dynamics
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 China key country dynamics
  • Fig. 60 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Japan key country dynamics
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 New Zealand key country dynamics
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea key country dynamics
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Taiwan key country dynamics
  • Fig. 72 Taiwan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Hong Kong key country dynamics
  • Fig. 74 Hong Kong market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Singapore key country dynamics
  • Fig. 76 Singapore market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Vietnam key country dynamics
  • Fig. 80 Vietnam market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Chile key country dynamics
  • Fig. 87 Chile market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa key country dynamics
  • Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia key country dynamics
  • Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 UAE key country dynamics
  • Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Egypt key country dynamics
  • Fig. 96 Egypt market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Qatar key country dynamics
  • Fig. 98 Qatar market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- blood-based biomarker for sports medicine market